RecruitingPhase 1NCT05504837
A Study Assessing KB407 for the Treatment of Cystic Fibrosis
KB407-02 A Phase 1 Study of Inhaled KB407, a Replication-Defective, Non-Integrating Vector Expressing Human Cystic Fibrosis Transmembrane Conductance Regulator, for the Treatment of Cystic Fibrosis
Sponsor
Krystal Biotech, Inc.
Enrollment
12 participants
Start Date
Jun 30, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
This study will evaluate safety and tolerability of ascending doses of nebulized KB407 in adults with cystic fibrosis.
Eligibility
Min Age: 18 Years
Inclusion Criteria8
- The subject must have read, understood, and signed an Institutional Review Board/Ethics Committee (IRB/IEC) approved Informed Consent Form and must be able to and willing to follow study procedures and instructions
- Subjects aged 18 years or older at the time of Informed Consent
- A confirmed diagnosis of CF as defined by clinical signs and symptoms of CF and at least one of the following:
- A historical sweat chloride value >60 mmol/L
- Two copies of a disease causing mutation in the CFTR gene
- Clinically stable in the opinion of the Investigator
- Percent predicted FEV1 ≥40% and ≤100% of the predicted normal for age, gender, and height at Screening
- Resting oxygen saturation ≥92% on room air at Screening
Exclusion Criteria14
- Initiation of any new chronic therapy (eg, CFTR modulator, hypertonic saline, inhaled antibiotic) or any change in chronic therapy (excluding pancreatic enzyme replacement therapy) within 28 days prior to the first dose
- Hospitalization, sinopulmonary infection, CF exacerbation, or other clinically significant infection or illness 14 days prior to the first dose that, in the opinion of the Investigator, may confound study results
- Treatment for Burkholderia cenocepacia, Burkholderia dolosa, or Nontuberculosis Mycobacteria infection within 3 months prior to the first dose
- Participation in another clinical study or treatment with an investigational agent 30 days or 5 half-lives, whichever is longer, prior to the first dose
- History of or listed for solid organ transplantation
- Any condition (including a history or current evidence of substance abuse or dependence, uncontrolled asthma, or is considered to be immunocompromised) that, in the opinion of the Investigator, would impact a subject's ability to complete all study-related procedures and/or poses an additional risk to the assessment of safety of KB407
- An active oral herpes infection 30 days prior to the first dose
- Has received a vaccine within 72 hours prior to the first dose or has a planned vaccination during the treatment period
- Women who are pregnant or nursing
- Subject who is unwilling to comply with contraception requirements per protocol
- Clinically significant abnormalities of hematology or chemistry testing at Screening that the Investigator believes may interfere with the assessment of safety and/or efficacy of the study treatment
- Subject has a known hypersensitivity to inhaled glycerol
- Subject is known to be noncompliant or is unlikely to comply with the requirements of the study protocol in the opinion of the Investigator
- Bronchoscopy participants only: Unable to tolerate bronchoscopy procedure and airway sampling, in the opinion of the Investigator
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
BIOLOGICALKB407 (Nebulization)
Nebulized solution of KB407, a replication-defective HSV-1 expressing full length human CFTR
Locations(5)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05504837
Related Trials
Natural History of Noncirrhotic Portal Hypertension
NCT024177401 location
Role of Genetic Factors in the Development of Lung Disease
NCT000015322 locations
Development of Non-Invasive Prenatal Diagnosis for Single Gene Disorders
NCT061474141 location
Impact of Sinus Surgery on Individuals With Cystic Fibrosis
NCT044694399 locations
Maralixibat in Patients With Cystic Fibrosis and Constipation
NCT064133681 location